Regeneron Pharmaceuticals (REGN) Leases (2013 - 2025)

Regeneron Pharmaceuticals has reported Leases for 12 years, with the latest figure at $576.7 million in Q4 2025.

• For the quarter ending Q4 2025, Leases fell 2.45% year-over-year to $576.7 million; the trailing twelve-month figure through Dec 2025 stood at $576.7 million (down 2.45% YoY), and the FY2025 full-year result was $576.7 million, down 2.45% from the prior year.
• Leases for Q4 2025 stood at $576.7 million, down from $591.2 million in the prior quarter.
• The five-year high for Leases was $631.3 million in Q4 2021, with the low at $576.7 million in Q4 2025.
• Average Leases over 5 years is $605.0 million, with a median of $605.7 million recorded in 2023.
• Year-over-year, Leases slipped 1.74% in 2022 and declined 2.45% in 2025.
• Tracing REGN's Leases over 5 years: stood at $631.3 million in 2021, then dropped by 1.74% to $620.3 million in 2022, then dropped by 2.35% to $605.7 million in 2023, then decreased by 2.39% to $591.2 million in 2024, then decreased by 2.45% to $576.7 million in 2025.
• The last three Leases figures came in at $576.7 million (Q4 2025), $591.2 million (Q4 2024), and $605.7 million (Q4 2023), per Business Quant data.

Peer Comparison